source
- Novartis secures supplemental FDA approval to market repurposed antibiotic Lamprene in the USNovartis has obtained a supplemental approval from the U.S. Food and Drug Administration for its drug Lamprene, allowing it to be sold as an antibiotic. Lamprene, originally developed decades ago…
- BioNTech's head and neck cancer vaccine fails to meet first primary endpoint in pivotal trialBioNTech reported that its experimental mRNA vaccine targeting head and neck cancer did not achieve one of the two primary goals in a pivotal study. The trial was designed to evaluate the vaccine’…